Illumina, Inc. (ILMN) stock
Close on Nov 11, 2026Market cap $32.20BP/E 36.5Yield –
Illumina, Inc. grew revenue 5.8% to $4.54B over the twelve months to Sep 27, 2026. Operating income rose 23.1% to $960.00M, moving the operating margin from 18.2% to 21.2%. Free cash flow was $1.06B, up 5.7% from a year earlier. At the latest close the market valued the company at $32.20B, 36.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 27, 2026
Valuation
- Market cap
- $32.20B
- P/E ratio
- 36.5
- Price to sales
- 7.09
- Price to book
- 10.24
- Dividend yield
- –
- Free cash flow yield
- 3.28%
Fundamentals
- Revenue
- $4.54B
- Net income
- $895.00M
- EPS, diluted
- $5.83
- Free cash flow
- $1.06B
- Book value per share
- $20.42
- Diluted shares
- 154M
Trading
- Next earnings
- Feb 4, 2027 (estimated, after the close)
- Previous close
- $214.91
- Open
- $219.97
- Day's range
- $212.74 – $227.71
- Volume
- 1,865,341
- Average volume (20 days)
- 2,354,597
- Index membership
- S&P MidCap 400 (since Aug 2024), Russell 1000, Russell 3000
- Beta (5 years)
- 1.38
- 52-week range
- $112.65 – $309.35
- RSI (14 days)
- 36.8
- Volatility (1 year)
- 48.4%
- Relative volume
- 0.72×
- WACC
- 11.4%
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ILMN | S&P 500 | Difference | ILMN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.5% | -2.4% | −21.0 pts | ||
| 3 months | +10.4% | -1.2% | +11.6 pts | ||
| Year to date | +62.3% | +12.3% | +50.1 pts | ||
| 1 year | +73.7% | +12.4% | +61.2 pts | ||
| 3 years | +126.6% | +78.8% | +47.8 pts | +31.4% | +21.4% |
| 5 years | -42.7% | +75.2% | −117.9 pts | -10.5% | +11.9% |
| 10 years | +61.9% | +311.1% | −249.2 pts | +4.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Illumina filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Update
- Results
About Illumina
Laboratory Analytical Instruments
Illumina, Inc. develops and provides genetic analysis solutions, focusing on sequencing- and microarray-based technologies. The company supplies integrated platforms, specialized instruments, and consumable reagents that enable researchers and healthcare specialists to analyze genetic variation and biological function. Its offerings support a broad range of life science applications, including clinical diagnostics, oncology, reproductive health, and genomics research. Customers primarily include academic and research institutions, clinical laboratories, pharmaceutical and biotechnology companies, and genomic centers.
Company profile, executives and historyIllumina stock: common questions
What is Illumina's stock price?
ILMN closed at $212.93 on Nov 11, 2026, down 0.92% on the day. Over the past 52 weeks it traded between $112.65 and $309.35.
What is Illumina's market cap?
Illumina was worth $32.20B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ILMN's P/E ratio?
ILMN trades at 36.5 times earnings, based on diluted earnings per share of $5.83 over the twelve months to Sep 27, 2026.
How much revenue does Illumina make?
Illumina reported revenue of $4.54B for the twelve months to Sep 27, 2026, up 5.8% from a year earlier.
Does Illumina pay a dividend?
No. Illumina has not paid a cash dividend over the last twelve months.
When does Illumina report earnings next?
Illumina is expected to report Q4 FY2026 results on Feb 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ILMN stock performed over the past year?
Including dividends, ILMN returned +73.7% over the past year, against +12.4% for the S&P 500.
How many ILMN shares are sold short?
8M shares were sold short at the latest FINRA report, 5.34% of the float, or 3.7 days of average trading volume.
Who are Illumina's competitors?
Companies most similar to Illumina by business, industry and size include RVTY, A, BRKR, BIO, MTD.
See a number that looks wrong?